Introduction {#s1}
============

Gastric cancer (GC) represents the fourth most common cancer and the second leading cause of cancer-related mortality worldwide [@pone.0071979-Jemal1]. The highest incidence and mortality rates are observed in East Asia, predominantly in China [@pone.0071979-Jemal1]. Remarkable improvements have been made to date in comprehensive treatment strategies of combined surgery, chemotherapy, radiotherapy, and targeted therapy, but GC patients still have a poor prognosis, with 5-year overall survival rates of 30% [@pone.0071979-Santoro1]. Although TNM classification has been widely considered as the best available clinical measure of tumor aggression and prognosis, obvious differences exit even among patients in the same stage [@pone.0071979-Catalano1]. Moreover, multiple genetic and epigenetic alterations are implicated in the multistep process of human stomach carcinogenesis and development [@pone.0071979-Resende1]. Therefore, discovery of readily accessible molecular markers and their application in incorporated with traditional cancer diagnosis, staging and prognosis could to a large extent be helpful for the improvement of early diagnosis, screening of high-risk individuals, as well as patient care [@pone.0071979-Ludwig1]. In recent years, increased studies had focused on the detection of genetic variants that could play roles in the development and progression of gastric cancer [@pone.0071979-Becker1].

Zinc finger (ZnF) gene family constitute one of the largest gene families, accounting for about 3% of the genes of the human genome [@pone.0071979-Klug1], and serve important functions in a diverse array of developmental events and cellular processes, such as control of cellular proliferation, differentiation, development and death [@pone.0071979-Matthews1]. Myelin transcription factor 1 (MYT1, or neural zinc finger 2 (NZF2)) and its homologue MYT1-like (MYT1L, or NZF1) are the two main members of MYT/NZF family transcription factors, each of which contains six copies of a ZnF with a C~2~HC consensus sequence. They are highly related and display a high degree of identity (91% for the finger regions and 62% at the protein level) [@pone.0071979-Stevens1], [@pone.0071979-Kim1]. Moreover, both proteins recruit the same histone deacetylases to regulate neural transcription via their interaction with Sin3B [@pone.0071979-Romm1], pointing to similar regulatory functions in neurogenesis. In order to elucidate the radioimmunotherapy molecular mechanisms of the treatment of gastric cancer cells expressing d9-E-cadherin with ^213^Bi-d9MAb, Seidl et al. [@pone.0071979-Seidl1] quantified 380 gene expression of ^213^Bi-treated tumor cells and found that ^213^Bi-induced cell death was initiated by G2 arrest and up-regulation of several genes, including MYT1. In addition, a cytology study revealed that the c-Jun N-terminal kinase -mediated phosphorylation of MYT1, accompanying with MYT1 overexpression, played an important role in UVA-induced apoptosis and the suppression of skin carcinogenesis [@pone.0071979-Choi1]. Although MYT1L itself has not previously been reported to associated with carcinoma, it is highly homologous to MYT1 [@pone.0071979-Stevens1], [@pone.0071979-Kim1] and the loss of MYT1 function may be compensated by MYT1L activity [@pone.0071979-Wang1]. So we hypothesize that MYT1L gene may also be linked to gastric cancer. Yang et al. analyzed 444,044 germline genetic single nucleotide polymorphisms (SNPs) in an ethnically diverse group of 2,534 children with acute lymphoblastic leukemia and provided significant evidences that a locus at 2p25.3 (rs17039396) in MYT1L gene exhibits the strongest association with relapse of disease [@pone.0071979-Yang1]. Therefore, we conduct this study to examine whether MYT1L rs17039396 polymorphism has potential significance as molecular prognostic markers for gastric cancer, which will help further define sub-populations who are at higher risk of poor disease and consequently require more aggressive treatment and more rigorous postoperative follow up.

Materials and Methods {#s2}
=====================

Study population {#s2a}
----------------

The whole study was approved by the Institutional Review Board of Nanjing Medical University (Nanjing, China), and each of the patients signed an informed consent on the use of clinical specimens for gene polymorphisms analyses. In this retrospective study, 944 patients with histopathologically confirmed gastric cancer who had received surgical resection between January 1999 and December 2006 were recruited from Yixing People\'s Hospital, (Yixing, Jiangsu Province, China). None have received prior radiotherapy or chemotherapy before surgery and not all of them have received adjuvant chemotherapy. 944 Formalin-Fixed and Parrffin-Embedded samples were obtained from the department of pathology of this hospital. The end point was overall survival (OS), which was calculated from the date of surgery until death or the last follow-up in March 2009. Death dates were confirmed by review of death certificates of inpatient and outpatient records or obtained through follow-up telephone calls. Patients still alive were censored. The maximum survival time was 119.0 months and the median survival time was 70.0 months. The demographic features and clinicopathological variables were summarized in [Table 1](#pone-0071979-t001){ref-type="table"}, which were obtained from the medical records of the patients. The TNM stage classification was evaluated according to the criteria of the 7th edition of the American Joint Committee on Cancer (AJCC).

10.1371/journal.pone.0071979.t001

###### Association between clinicopathological features and survival of gastric cancer.

![](pone.0071979.t001){#pone-0071979-t001-1}

  Variables                                                Patients, n = 909   Deaths, n = 421              MST (months)              Log-rank p      HR (95% CI)
  ------------------------------------------------------- ------------------- ----------------- ------------------------------------ ------------ -------------------
  Age (years)                                                                                                                                     
  ≤60                                                             428                197                         97                     0.431            1.00
  \>60                                                            481                224                         62                                1.01 (0.99--1.02)
  Sex                                                                                                                                             
  Male                                                            699                322                         70                     0.564            1.00
  Female                                                          210                99                          67                                1.07 (0.85--1.34)
  Tumor size                                                                                                                                      
  ≤5 cm                                                           566                238                         74                    \<0.001           1.00
  \>5 cm                                                          343                183                         48                                1.43 (1.18--1.73)
  Location                                                                                                                                        
  Non-cardia                                                      600                282                         67                     0.354            1.00
  Cardia                                                          309                139                         77                                0.91 (0.74--1.11)
  Histological types                                                                                                                              
  Intestinal                                                      386                150         77[§](#nt105){ref-type="table-fn"}    \<0.001           1.00
  Diffuse                                                         519                268                         50                                1.45 (1.19--1.77)
  Others                                                           4                  3                          11                               
  Differentiation[a](#nt102){ref-type="table-fn"}                                                                                                 
  Well to moderate                                                296                126                         77                    \<0.001           1.00
  Poorly                                                          473                230                         62                                1.15 (0.93--1.43)
  Mucinous/signet-ring cell                                       65                 32                          62                                1.19 (0.81--1.75)
  Depth of invasion[b](#nt103){ref-type="table-fn"}                                                                                               
  T1                                                              178                58          84[§](#nt105){ref-type="table-fn"}    \<0.001           1.00
  T2                                                              130                56          78[§](#nt105){ref-type="table-fn"}                1.42 (0.99--2.06)
  T3                                                               6                  3                          70                                1.42 (0.44--4.52)
  T4                                                              576                292                         51                                1.82 (1.38--2.42)
  Lymph node metastasis[c](#nt104){ref-type="table-fn"}                                                                                           
  N0                                                              360                130                         80                    \<0.001           1.00
  N1/N2/N3                                                        549                291                         47                                1.72 (1.41--2.13)
  Distant metastasis                                                                                                                              
  M0                                                              857                391                         74                     0.015            1.00
  M1                                                              52                 30                          26                                1.58 (1.09--2.29)
  TNM stage                                                                                                                                       
  I                                                               241                82                          83                    \<0.001           1.00
  II                                                              194                78                          71                                1.24 (0.91--1.69)
  III                                                             447                245                         39                                1.96 (1.52--2.52)
  IV                                                              27                 16                          27                                2.40 (1.41--4.11)
  Smoking                                                                                                                                         
  Non-smoker                                                      833                389                         97                     0.399            1.00
  Smoker                                                          76                 32                          65                                0.86 (0.60--1.23)
  Chemotherapy                                                                                                                                    
  No                                                              298                136                         74                     0.516            1.00
  Yes                                                             611                285                         60                                1.07 (0.87--1.31)

Abbreviation: MST, median survival time; HR, hazard ratio; CI, confidence interval; AJCC, American Joint Commission on Cancer.

Partial data were not available, and statistics were based on available data.

The information about the depth of invasion was not available for two patients; invaded depth of tumor was classified according to the criteria of AJCC 7th.

Lymph nodes were staged according to tumor-node-metastasis classification of the 7th edition of AJCC in which the number of lymph nodes with a metastasis of 1∼2, 3∼6 and ≥7 were classified as N1, N2 and N3, respectively.

Mean survival time was presented when the median survival time could not be measured.

Genotyping {#s2b}
----------

Genomic DNA was extracted from paraffin-embedded tumor bearing tissue using proteinase K digestion, followed by isopropanol extraction and ethanol precipitation. Genotyping of samples was conducted by multiplex SNaPshot technology using an ABI fluorescence-based assay allelic discrimination method (Applied Biosystems, Foster city, CA, USA), which has been described in detail in previous study [@pone.0071979-Zhang1]. The primers were designed to anneal immediately adjacent to the nucleotide at the mutation site: forward, 5′- TAT TAG TCT GAR TCT GCT GGC CTT TG -3′; reverse, 5′- GAC TTC ACC TCC ACC AGG ACC A-3′. The primers for extension were as follows: 5′-TTT CCT CCA CCA GGA CCA GAT TT-3′. The SNaPshot products were analyzed by using an ABI 3130 genetic analyzer (Applied Biosystems) and the genotypes were determined by GeneMapper Analysis Software version 4 (Applied Biosystems). Genotype analysis was performed by two investigators blinded to the survival end points. Genotyping was validated by sequencing a randomly selected 10% of samples, and the results were 100% concordant. However, 35 cases failed in genotyping because of poor DNA quality, which were excluded in further analysis. Finally, 909 gastric cancer patients were included in the analysis.

Statistical analysis {#s2c}
--------------------

Statistical analyses were carried out using SPSS version 16.0 for Windows (SPSS Inc., Chicago, IL, USA). Kaplan-Meier survival curves and the log-rank test were used for survival analysis. Univariate or multivariate Cox proportional hazard models was adopted to estimate the crude hazard ratios (HRs), adjusted HRs and their 95% confidence intervals (CIs), with adjustment for potential confounders. Moreover, Cox stepwise regression analysis was performed to asses the independent impacts of SNP or clinicopathological features on the overall survival after adjusting for other covariates, with a significance level of *P*\<0.05 for entering and *P*\>0.10 for removing the respective explanatory variables. Hardy-Weinberg equilibrium of alleles at individual loci was assessed by a goodness-of-fit χ^2^ test. All tests were two-sided and *P*\<0.05 was considered statistically significant.

Results {#s3}
=======

Associations between clinicopathological variables and overall survival {#s3a}
-----------------------------------------------------------------------

The final population of this study consisted of 909 patients. The patients characteristics and clinical information are summarized in [Table 1](#pone-0071979-t001){ref-type="table"}. In the follow-up period of 119 months, 421 patients died. There were 699 males (76.9%) and 210 females (23.1%), with the median age of 62 years ranging from 28 to 83 years. Clinicopathological characteristics including tumor size, histological types, differentiation, depth of invasion, lymph node metastasis, distant metastasis and TNM stage were significantly associated with survival time (log-rank *P*\<0.05). Specifically, patients with tumor size \>5 cm (MST, 48 months) had a 43% significantly higher risk of death (HR = 1.43, 95% CI = 1.18--1.73), compared with those with tumor size ≤5 cm (MST, 74 months), and the diffuse-type gastric cancer patients (MST, 50 months) had a 45% significantly higher risk of death (HR = 1.45, 95% CI = 1.19--1.773), than those intestinal-type patients (MST, 77 months). In addition, as the depth of invasion and TNM stage increased, the risk of death for gastric cancer showed a significant increase in a dose-response manner (log-rank *P*\<0.001).

Associations of MYT1L rs17039396 with clinical outcomes of GC {#s3b}
-------------------------------------------------------------

Among 944 specimens of GC patients, MYT1L rs17039396 was successfully genotyped in 909 specimens. The frequency of each genotypes was 57.0% (518 specimens) for the GG variant, 37.8% (344 specimens) for the GA variant, and 5.2% (47 specimens) for the AA variant. The genotype frequencies of MYT1L rs17039396 in the cases followed HWE (*P* = 0.21). The Kaplan-Meier survival analysis and Cox proportional hazard models were used to assess the prognostic effect of MYT1L rs17039396 on GC patients in different genetic models ([Table 2](#pone-0071979-t002){ref-type="table"}). No significant associations were observed between the MYT1L rs17039396 genotypes and OS of GC patients in any genetic models. We further evaluated the associations by stratified analysis of tumor location and histological types. In the overall model, MYT1L rs17039396 polymorphism was associated with the survival of cardia cancer (log-rank *P* = 0.015, [Fig. 1](#pone-0071979-g001){ref-type="fig"}). Survival time of patients with the GA genotype (MST 98 months) was significantly different compared with that of patients with the GG genotype (MST 47 months), who had a 44% higher risk of death (HR = 0.56, 95% CI = 0.39--0.81). In the dominant model, a significantly lower risk of death (HR = 0.57, 95% CI = 0.40--0.81) was found (log-rank *P* = 0.001), as shown in [Fig. 2](#pone-0071979-g002){ref-type="fig"}.

![Overall survival curve in relation to MYT1L rs17039396 polymorphism in patients with cardia gastric cancer in overall model.\
[Figure 1](#pone-0071979-g001){ref-type="fig"} represents the Kaplan-Meier survival curve in relation to the effect of MYT1L variants on overall survival of the patients with cardia gastric cancer in overall model and the *P* value of log-rank test received statistical significance.](pone.0071979.g001){#pone-0071979-g001}

![Overall survival curve in relation to MYT1L rs17039396 polymorphism in patients with cardia gastric cancer in dominant model.\
[Figure 2](#pone-0071979-g002){ref-type="fig"} represents the Kaplan-Meier survival curve in relation to the effect of MYT1L rs17039396 polymorphism on overall survival of the patients with cardia gastric cancer in dominant model. Patients with GA or AA genotypes was at lower risk of death, compared with those with GG homozygotes. *P* value is 0.001, suggesting that MYT1L rs17039396 GA+AA genotypes were associated with better overall survival in 309 patients with cardia gastric cancer.](pone.0071979.g002){#pone-0071979-g002}

10.1371/journal.pone.0071979.t002

###### Association between MYT1L rs17039396 polymorphism and overall survival of gastric cancer.
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                    All patients                                                                         
  ---------------- -------------- ------------------- ----- ------------------------------------ ------- -------------------
  Overall model          GG               518          248                   56                   0.108         1.00
                         GA               344          147                   80                           0.84 (0.68--1.39)
                         AA               47           26    52[§](#nt108){ref-type="table-fn"}           1.21 (0.80--1.81)
  Dominant model         GG               518          248                   56                   0.185         1.00
                      GA or AA            391          173                   78                           0.88 (0.72--1.06)
                                   Non-cardia cancer                                                     
  Overall model          GG               344          158                   74                   0.134         1.00
                         GA               228          106                   67                           1.01 (0.79--1.29)
                         AA               28           18    22[§](#nt108){ref-type="table-fn"}           1.62 (0.99--2.64)
  Dominant model         GG               344          158                   74                   0.546         1.00
                      GA or AA            256          124                   63                           1.07 (0.84--1.35)
                                     Cardia cancer                                                       
  Overall model          GG               174          90                    47                   0.005         1.00
                         GA               116          41                    98                           0.56 (0.39--0.81)
                         AA               19            8    97[§](#nt108){ref-type="table-fn"}           0.67 (0.33--1.38)
  Dominant model         GG               174          90                    47                   0.001         1.00
                      GA or AA            135          49                    97                           0.57 (0.40--0.81)

MST, median survival time; HR, hazard ratio; CI, confidence interval.

Hazard Ratio (HR) adjusted for age, sex, TNM stage.

Mean survival time was presented when the median survival time could not be measured.

Further stratified analyses and stepwise Cox regression model for survival among cardia cancer {#s3c}
----------------------------------------------------------------------------------------------

The contribution of MYT1L rs17039396 A allele to the improved survival of cardia gastric cancer patients were further evaluated by stratified analysis of tumor size, histological types, degree of differentiation, depth of invasion, lymph node metastasis, distant metastasis and TNM stage. As a result, in the stratified analysis among cardia gastric cancer, we found that this protect effect was more prominent among subgroups of patients with tumor size ≤5 cm (adjusted HR = 0.34, 95%CI = 0.19--0.64), well-moderate gastric cancer (adjusted HR = 0.59, 95%CI = 0.35--0.98), no lymph-node metastasis (adjusted HR = 0.49, 95%CI = 0.31--0.76), no distant metastasis (adjusted HR = 0.59, 95%CI = 0.41--0.84) ([Table 3](#pone-0071979-t003){ref-type="table"}). Cox stepwise regression analysis was conducted to evaluate the independent effect of clinicopathological variables and rs17039396 SNP on the OS of the patients with cardia gastric cancer. As shown in [Table 4](#pone-0071979-t004){ref-type="table"}, two variables (TNM stage and MYT1L rs17039396) were included in the regression model by stepwise selection of the covariant variables and rs17039396 SNP was shown to be an independent protective factor for cardia cancer with a 44% decreased risk (HR = 0.56, 95%CI = 0.39--0.79, *P* = 0.001).

10.1371/journal.pone.0071979.t003

###### Stratified analysis of MYT1L rs17039396 polymorphism among cardia cancer patients.
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  Variables                    Genotypes (deaths/patients)   HR (95% CI)[a](#nt110){ref-type="table-fn"}          *P*          
  --------------------------- ----------------------------- --------------------------------------------- -------------------- -------
  Total                                  90/174                                49/135                      0.57 (0.40--0.81)    0.002
  Tumor size                                                                                                                   
  ≤5 cm                                  53/115                                 31/89                      0.34 (0.19--0.64)    0.001
  \>5 cm                                  37/59                                 18/46                      0.67 (0.43--1.05)    0.082
  Histological types                                                                                                           
  Intestinal                              42/84                                 26/72                      0.61 (0.38--1.01)    0.053
  Diffuse                                 48/90                                 26/72                      0.52 (0.32--1.07)    0.072
  Differentiation                                                                                                              
  Well to moderate                        42/75                                 23/57                      0.59 (0.35--0.98)    0.042
  Poorly                                  37/77                                 23/61                      0.67 (0.33--1.13)    0.129
  Mucinous/signet-ring cell                5/8                                   1/6                       0.13 (0.01--1.39)    0.092
  Depth of invasion                                                                                                            
  T1                                      4/19                                  5/20                       1.22 (0.30--4.99)    0.778
  T2                                      13/28                                 7/20                       0.70 (0.27--1.79)    0.455
  T3                                       0/1                                   0/0                              ---          
  T4                                     72/125                                 36/92                      0.52 (0.35--1.18)    0.062
  Lymph node metastasis                                                                                                        
  N0                                      30/69                                 17/56                      0.49 (0.31--0.76)    0.002
  N1/N2/N3                               60/105                                 32/79                      0.64 (0.36--1.17)    0.148
  Distant metastasis                                                                                                           
  M0                                     65/166                                48/131                      0.59 (0.41--0.84)    0.004
  M1                                       5/8                                   1/4                              ---          
  TNM stage                                                                                                                    
  I                                       14/37                                 8/32                       0.55 (0.23--1.32)    0.181
  II                                      21/45                                 12/35                      0.75 (0.37--1.54)    0.437
  III                                     52/88                                 28/67                      0.46 (0.28--1.05)    0.202
  IV                                       3/4                                   1/1                       1.47 (0.03--66.46)   0.842

HR, hazard ratio; CI, confidence interval.

Hazard Ratio (HR) adjusted for age, sex.

10.1371/journal.pone.0071979.t004

###### Stepwise Cox regression analysis on the survival of cardia cancer.
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  Variables                                β       SE      HR       95%CI       *P* value
  ------------------------------------- -------- ------- ------ -------------- -----------
  Age[a](#nt112){ref-type="table-fn"}    0.006    0.005   1.01   (0.99--1.02)     0.235
  Sex                                    0.066    0.115   1.07   (0.85--1.34)     0.567
  TNM stage                              0.388    0.110   1.47   (1.19--1.83)    \<0.001
  rs17039396 (GG *vs* GA/AA)             −0.582   0.179   0.56   (0.39--0.79)     0.001

β, regression coefficient; SE, standard error; HR, hazard ratio; CI, confidence interval.

Age was included as a continuous variable in the Cox stepwise regression analysis.

Discussion {#s4}
==========

In the present study, we investigated the effect of the MYT1L rs17039396 SNP on the progression and survival of GC. Our results indicated that the heterozygote genotype (GA) had a significantly higher survival rate than homozygote genotype (GG), and the association was also observed when analyzing the dominant model (GA/AA *vs* GG), suggesting that the MYT1L rs17039396 A allele may be associated with survival of GC.

In our results, MYT1L rs17039396 was significantly correlated with improved survival of cardia carcinoma but not noncardia carcinoma of the stomach. There is recently increasing evidence that the cardia type of gastric cancer has different characteristics from the noncardia type in terms of aetiology, pathology, carcinogenesis, biological behavior, prognosis and even genetic background. For example, Kamangar et.al reported that H. pylori infection was a strong risk factor for non-cardia gastric cancer but was inversely associated with the risk of gastric cardia cancer [@pone.0071979-Kamangar1]. Compared with the non-cardia gastric cancer, gastric cardia cancer is associated with reflux symptoms, predominance in white males and a greater frequency of differentiated-type tumors [@pone.0071979-Tajima1]. Furthermore, a greater tendency towards poorly differentiated histology, lymph node metastasis, advanced pathologic TNM stage, and a poor prognosis were described as characteristics of cardia carcinoma [@pone.0071979-Kim2]. Therefore, it is rational to consider cardia carcinoma as a specific category of GC. It could be said that the indiscriminate combination of the two subtypes of GC may mask or produce underestimation of the strength of the authentic associations. In the stratified analyses, when confined to the patients with some special clinicopathological features such as tumor size ≤5 cm, well-moderate gastric cancer, no lymph-node metastasis, no distant metastasis, the survival time for the subjects carrying GA or AA genotypes was longer than those for GG genotypes, indicating that the abovementioned prognostic factors may have a combined effect with rs17039396 on the superior OS of cardia gastric cancer.

The MYT1L gene (MIM:613084) maps to chromosome 2p25.3 with 542161 bp in length, comprising twenty-five exons (<http://www.ncbi.nlm.nih.gov/GENE/>). Exon 1 to exon 5 and the distal part of exon 25 are untranslated regions, while the other 19 exons and the proximal part of exon 25 are coding regions. Wang et al. [@pone.0071979-Wang2] found that rs3748989 in exon 9 of MYT1L gene conferred a predisposition to major depressive disorder. A case--control study with a relatively large sample size showed that rs17039584 located near 5′ untranslated regions and rs10190125 in intron 1 of MYT1L gene were significantly associated with Schizophrenia [@pone.0071979-Li1]. Our study revealed a significant correlation of rs17039396 located at intron 3 with cardia gastric cancer. Although the roles of these SNPs in MYT1L gene expression and their precise functional and biological significances have been largely unknown, it is not difficult to speculate that antonymous mutations occurring in exons in coding regions could lead to substitutions of amine acids, change the structure of coding-proteins, and subsequently affect their biological functions. Whereas, what is the mechanism of action of intronic polymorphic variants? It has increasingly become apparent that intronic germline variations might involve alterations of gene regulation and transcript processing, or produce splicing variants [@pone.0071979-Pagani1]--[@pone.0071979-Sjakste1]. Recently, a T to G change at the 309^th^ nucleotide in the first intron of the MDM2 gene (SNP309) has been found and shown to increase the affinity of the transcriptional activator Sp1, resulting in higher levels of MDM2 RNA and protein and the subsequent attenuation of the p53 pathway [@pone.0071979-Bond1]. Subsequently, a case-control study including 438 controls and 410 patients with sporadic gastric carcinoma provided evidence supporting the association of MDM2 SNP309 with both an increased susceptibility to gastric carcinoma and poor prognosis [@pone.0071979-Ohmiya1]. Furthermore, Narla et al. [@pone.0071979-Narla1] reported that a relatively common intronic polymorphism of KLF6 gene enhances alternative splicing and is associated with increased prostate cancer risk. Given above-mentioned evidences, it is reasonable to presume that MYT1L intronic polymorphisms might exert their functions through alternative gene expression or splicing variants that permit the generation of protein isoforms having different biology functions. To our knowledge, there have been no published attempts to characterize the functional implications of the MYT1L intron polymorphisms. Hence, the clear molecular mechanisms by which genetic variants exert their biological implications warrants further experimental investigation.

The MYT1L protein plays a crucial role in CNS development, so it is rational to presume that changes in its expression level or function resulted from genetic variations could lead to psychiatric disorders [@pone.0071979-Wang2]--[@pone.0071979-Li1]. However, exactly how this protein affect the susceptibility, progression or prognosis of tumor is far from clear. The MYT1L protein is a member of the myelin transcription factor 1 family that modulates proliferation and differentiation of oligodendrocytes by controlling the transcriptional activity of downstream genes involved in lineage specification [@pone.0071979-Vrijenhoek1]. In addition, Riley et al. [@pone.0071979-Riley1] hypothesized that MYT1L regulates ZNF804A gene expression in schizophrenia patients. Based on these evidences, we hypothesized that genetic variation in MYT1L gene might affects its function to regulate expression levels of sets of tumor-related genes, and consequently involves in carcinogenesis. Another plausible explanation of its association with gastric cancer lies in controlling cell-cycle progression. Except for the transcriptional activity, MYT1 also functions as a cell cycle-regulated kinase. Dai et al. [@pone.0071979-Dai1] indicated that the upregulation of Myt1 and Wee1 induced the phosphorylation of Cdc2 leading to G2/M arrest in normal cell line. The p53 tumor suppressor protein plays a crucial role in tumorigenesis and prevents the proliferation of cancer-prone cells primarily by controlling cell-cycle progression and apoptosis. Passer et al. [@pone.0071979-Passer1] found that up-regulated expression of TSAP6, transcriptionally activated by p53, could augment MYT1 activity, resulting in cell-cycle delay and the suppression of growth of cancer-prone cells. Furthermore, a more recent study investigating the functions of MYT1 in checkpoint recovery followed by DNA damage revealed that downregulation of MYT1 potentiated with DNA damage to inhibit tumor cell growth in tumor xenograft mice models, implicating MYT1 as a potential target for anti-cancer therapies [@pone.0071979-Chow1]. These data highlight the contribution of MYT1 protein to regulation of cell-cycle progression and implicate it as a potential target for anti-cancer therapies. Although MYT1L has not be reported to function to modulate the cell-cycle progression, it is highly homologous to MYT1 [@pone.0071979-Stevens1]--[@pone.0071979-Kim1] and the loss of MYT1 function may be compensated by MYT1L activity [@pone.0071979-Wang1]. So it is plausible that MYT1L protein may have a similar role in regulation of cell-cycle process and their changes stemming from genetic variation may be involved in tumorgentic process. Taken together, the presented findings of the potential involvement of MYT1L gene in antitumorigenesis prompts us to further characterize its structure, biological function, and interaction with other partners by in vitro or vivo studies.

Some limitations of the present study should be addressed. First, only one SNP in MYT1L is evaluated, and it is possible that some other important SNPs are neglected or the observed associations may be due to other polymorphisms in linkage disequilibrium with the rs17039396 polymorphism. Second, Helicobacter pylori, as a known crucial factor in gastric carcinogenesis, was not considered due to the lack of related follow-up information. Finally, for validation of the genotype--phenotype relationship, further investigation is underway to clarify the association between rs17039396 polymorphism and expression levels of MYT1L protein in gastric cancer tissues and will be reported separately.

In conclution, our results represent the first demonstration that MYT1L rs17039396 SNP may be associated with the prognosis of cardia cancer patients. The survival of patients in the dominant model was significantly better than the survival in the overall model, suggesting that the mutant allele may serve as a suitable marker for predicting the survival of cardia cancer patients, especially in a Chinese population. Consequently, testing for MYT1L rs17039396 SNP, combined with other traditional prognostic factors may significantly help distinguish a subgroup of patients with poor prognosis, thereby helping to refine therapeutic decisions in the treatment of gastric cancer.
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